Regeneron Pharmaceuticals, Inc. (REGN) Misses Q1 EPS by 36c

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q1 EPS of $0.58, $0.36 worse than the analyst estimate of $0.94. Revenue for the quarter came in at $626 million versus the consensus estimate of $609.04 million.

For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• Affirm Holdings (AFRM) PT Raised to $110 at Bernstein SocGen Group
• T. Rowe Price (TROW) PT Raised to $110 at TD Cowen